Suppr超能文献

基于国内生产总值的成本效益阈值之后还有什么?

What next after GDP-based cost-effectiveness thresholds?

作者信息

Chi Y-Ling, Blecher Mark, Chalkidou Kalipso, Culyer Anthony, Claxton Karl, Edoka Ijeoma, Glassman Amanda, Kreif Noemi, Jones Iain, Mirelman Andrew J, Nadjib Mardiati, Morton Alec, Norheim Ole Frithjof, Ochalek Jessica, Prinja Shankar, Ruiz Francis, Teerawattananon Yot, Vassall Anna, Winch Alexander

机构信息

Center for Global Development, London, SW1P 3SE, UK.

National Treasury, Pretoria, 0002, South Africa.

出版信息

Gates Open Res. 2020 Nov 30;4:176. doi: 10.12688/gatesopenres.13201.1. eCollection 2020.

Abstract

Public payers around the world are increasingly using cost-effectiveness thresholds (CETs) to assess the value-for-money of an intervention and make coverage decisions. However, there is still much confusion about the meaning and uses of the CET, how it should be calculated, and what constitutes an adequate evidence base for its formulation. One widely referenced and used threshold in the last decade has been the 1-3 GDP per capita, which is often attributed to the Commission on Macroeconomics and  WHO guidelines on Choosing Interventions that are Cost Effective (WHO-CHOICE). For many reasons, however, this threshold has been widely criticised; which has led experts across the world, including the WHO, to discourage its use. This has left a vacuum for policy-makers and technical staff at a time when countries are wanting to move towards Universal Health Coverage This article seeks to address this gap by offering five practical options for decision-makers in low- and middle-income countries that can be used instead of the 1-3 GDP rule, to combine existing evidence with fair decision-rules or develop locally relevant CETs. It builds on existing literature as well as an engagement with a group of experts and decision-makers working in low, middle and high income countries.

摘要

世界各地的公共支付方越来越多地使用成本效益阈值(CETs)来评估一项干预措施的性价比,并做出覆盖范围决策。然而,对于CET的含义和用途、应如何计算以及构成其制定的充分证据基础的因素,仍然存在很多困惑。在过去十年中,一个被广泛引用和使用的阈值是人均国内生产总值的1至3倍,这通常归因于宏观经济委员会以及世界卫生组织关于选择具有成本效益的干预措施的指南(WHO-CHOICE)。然而,由于多种原因,这个阈值受到了广泛批评,这导致包括世界卫生组织在内的世界各地专家不鼓励使用它。在各国希望迈向全民健康覆盖之际,这给政策制定者和技术人员留下了一个空白。本文旨在通过为低收入和中等收入国家的决策者提供五个实用选项来填补这一空白,这些选项可用于替代1至3倍国内生产总值规则,将现有证据与公平决策规则相结合或制定与当地相关的CETs。它基于现有文献以及与一组在低收入、中等收入和高收入国家工作的专家和决策者的交流。

相似文献

1
What next after GDP-based cost-effectiveness thresholds?基于国内生产总值的成本效益阈值之后还有什么?
Gates Open Res. 2020 Nov 30;4:176. doi: 10.12688/gatesopenres.13201.1. eCollection 2020.
7
Cost-effectiveness thresholds: pros and cons.成本效益阈值:利弊
Bull World Health Organ. 2016 Dec 1;94(12):925-930. doi: 10.2471/BLT.15.164418. Epub 2016 Sep 19.

引用本文的文献

本文引用的文献

1
Valuing health outcomes: developing better defaults based on health opportunity costs.重视健康结果:基于健康机会成本制定更好的默认选项。
Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):729-736. doi: 10.1080/14737167.2020.1812387. Epub 2020 Sep 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验